Depression remains one of the most widespread mental health issues globally, impacting individuals’ emotions, thoughts, and daily functioning. Although many find relief through antidepressants, therapy, or a combination of both, some continue to struggle despite trying various treatments. This persistent form of depression, known as treatment-resistant depression, is often among the most challenging to address.
For those afflicted, symptoms tend to linger for years. They may experience ongoing sadness, loss of interest in activities they once enjoyed, fatigue, sleep disturbances, trouble concentrating, and feelings of despair.
Because traditional treatments don’t work for everyone, researchers are actively exploring new options. One emerging treatment gaining attention is psilocybin—a naturally occurring psychedelic compound found in certain types of mushrooms.
Over the past decade, multiple carefully designed clinical studies have indicated that psilocybin can help alleviate depressive symptoms, even in cases unresponsive to standard treatments. Though these findings are promising, much remains unknown about how psilocybin performs outside of clinical trials, in everyday healthcare settings. Clinical research often involves tightly controlled environments and selective participants, which can differ markedly from real-world practice.
To better understand its practical effects, researchers in Switzerland reviewed medical records from patients who received psilocybin at the Psychiatric University Hospital Zurich. Their objective was to see whether the positive outcomes observed in research could also be achieved through routine clinical care.
The study involved 19 patients with varying degrees of treatment-resistant depression—from mild to severe. Each patient underwent between one and four supervised psilocybin sessions as part of their treatment plan. The team then evaluated changes in depression symptoms before and after the therapy.
Results showed substantial improvement. Using clinician-rated depression scales, scores dropped significantly post-treatment. On average, patients’ scores decreased from about 31 out of 60 before treatment to around 20 out of 60 within six weeks after their last session. Patients also rated their own feelings of depression, which declined from an average of 32 out of 63 to 23 out of 63 after treatment. These changes suggest both healthcare providers and patients perceived meaningful symptom relief.
Side effects were monitored throughout. They occurred in 30 of the 40 treatment sessions, but most were mild and temporary—common issues included fatigue, headaches, and tearfulness. Crucially, no serious or long-lasting adverse effects were observed.
Scientists believe psilocybin functions differently from traditional antidepressants. It’s thought to temporarily enhance communication between different brain regions, helping individuals break free from rigid thought patterns and emotional loops. This increased neural flexibility might foster new perspectives on their experiences and feelings—potentially aiding recovery.
Interest in psychedelic-assisted therapies has surged in recent years, with studies focusing on depression, anxiety related to serious illness, addiction, and other mental health issues. While early results are optimistic, experts strongly recommend these treatments only be administered in carefully supervised medical settings.
This Swiss study provides valuable real-world evidence, suggesting that benefits seen in controlled research could translate into everyday healthcare environments. Nevertheless, the authors emphasize several limitations: the small sample size of only 19 patients, the absence of a control or placebo group, and the short follow-up period, leaving questions about the longevity of the improvements.
If you’re concerned about depression, consider exploring research on how dietary factors—like dairy products—might influence depression risk, or how B vitamins could play a preventive role against depression and anxiety. For broader mental health insights, recent studies also point to the potential impact of ultra-processed foods on mood and how extra-virgin olive oil might help reduce depressive symptoms.
This research was published in The Lancet Regional Health—Europe, based on findings from the Psychiatric University Hospital Zurich.